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Abstract
Toll-like receptors (TLRs) recognize microbial/viral–derived components that trigger innate immune response and
conflicting data implicate TLR agonists in cancer, either as protumor or antitumor agents. We previously demon-
strated that TLR3 activation mediated by its agonist poly(I:C) induces antitumor signaling, leading to apoptosis of
prostate cancer cells LNCaP and PC3 with much more efficiency in the former than in the second more aggressive
line. The transcription factor hypoxia-inducible factor 1 (HIF-1) regulates several cellular processes, including apoptosis,
in response to hypoxia and to other stimuli also in normoxic conditions. Here we describe a novel protumor machinery
triggered by TLR3 activation in PC3 cells consisting of increased expression of the specific I.3 isoform of HIF-1α and
nuclear accumulation of HIF-1 complex in normoxia, resulting in reduced apoptosis and in secretion of functional vas-
cular endothelial growth factor (VEGF). Moreover, we report that, in the less aggressive LNCaP cells, TLR3 activation
fails to induce nuclear accumulation of HIF-1α. However, the transfection of I.3 isoform of hif-1α in LNCaP cells allows
poly(I:C)–induced HIF-1 activation, resulting in apoptosis protection and VEGF secretion. Altogether, our findings dem-
onstrate that differences in the basal level of HIF-1α expression in different prostate cancer cell lines underlie their dif-
ferential response to TLR3 activation, suggesting a correlation between different stages of malignancy, hypoxic gene
expression, and beneficial responsiveness to TLR agonists.
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Introduction
Hypoxia-inducible factor 1 (HIF-1) is a basic helix-loop-helix tran-
scription factor that regulates a number of genes required for hypoxic
response through binding specific regions of their promoters, named
hypoxia-responsive elements [1–3]. HIF-1 is active only as a hetero-
dimer of HIF-1α and HIF-1β subunits. HIF-1β is constitutively ex-
pressed in all cell types, whereas HIF-1α levels are tightly controlled.
Under normoxia, HIF-1α levels are low because of the proteasomal deg-
radation initiated by oxygen-sensing prolyl hydroxylases. Under hypoxic
conditions, HIF-1α is stabilized and freely binds HIF-1β, forming
active HIF-1 transcription complex [4]. In humans, three different
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isoform of hif-1α were recently described: I.1, ubiquitous and respon-
sible for the transcriptional activity of the hypoxic response; I.2, ex-
pressed specifically in the testis and plays a dominant-negative
function with respect to the I.1 isoform [5]; I.3, has recently been
found highly expressed in peripheral blood leukocytes, in the thymus,
and in activated T cells [6].
It has been clearly demonstrated that HIF-1 regulates genes relevant
to cancer progression reviewed in Dery et al. [7], especially as a predic-
tor of clinical outcome in patients with adenocarcinomas [8]. In par-
ticular, HIF-1α has emerged as a potential prognostic biomarker in the
proteomic assessment of prostate cancer [9] because clinical observa-
tion of high-grade prostate intraepithelial neoplasia lesion (precursor
of most prostate adenocarcinoma, PCa) showed increased HIF-1α ex-
pression [10], and HIF-1α up-regulation in PCa as well as in prostate
cancer bone metastases has been observed [11]. PCa is a prevalent tu-
mor among elderly men, and survival benefit with current PCa ther-
apies is often limited [12]. Indeed, standard pharmacological therapy,
consisting of withdrawal of androgens, leads only to transient regres-
sion of the disease, and there is no cure for prostate cancer once it be-
comes refractory to androgen. Although the HIF-1α protein is mainly
induced by hypoxic conditions, other stimuli can strongly increase the
HIF-1 complex in normoxic conditions and modulate the transcrip-
tion of hypoxic genes. These stimuli include reactive nitrogen–derived
[13] or oxygen-derived radicals [14], cytokines [15,16], growth factors
[17], and T-cell receptor stimulation [6,18]. Interestingly, a variety of
molecular components derived from bacteria or viruses have also been
described to activate HIF-1α in normoxia through specific Toll-like
receptors (TLRs) [19–21]. These are a group of transmembrane pro-
teins (11 in humans) that recognize pathogen-associated molecular
patterns as well as endogenous damage-associated molecular patterns
[22] and elicit pathogen-induced and noninfectious inflammatory re-
sponses [23]. TLRs were initially detected only on immune cells [24],
but recent studies demonstrate that tumor cells express functional
TLRs and that TLR signaling can promote opposite outcomes: tumor
growth and immune evasion or apoptosis and cell cycle arrest [25–28].
The TLR3-ligand poly(I:C) mimics the action of double-stranded
RNA (dsRNA), the genetic material of many viruses, and TLR3 en-
gagement, directly inhibits cell proliferation, and induces tumor cell
death [28,29]. We have previously demonstrated that LNCaP cells,
an androgen-dependent human prostate cancer cell line, are sensitive
to poly(I:C)–induced apoptosis, whereas PC3 cells, a more aggressive
androgen-independent prostate cancer cell line, show a weak sensitiv-
ity to the same stimulus [27]. Recently, a number of articles reported
the ability of HIF-1 complex to mediate the resistance to several apop-
totic stimuli by inducing antiapoptotic genes such as Bcl-xL, survivin,
andMCL-1 described to be HIF-1 target genes [30–32]. On the basis
of these data, we have hypothesized that the limited response of PC3
cells to poly(I:C) could be due to the induction of a parallel protumoral
signal involving HIF-1 complex activation. Here we report evidence
showing that poly(I:C) treatment activates TLR3 and enhances the
transcription of the I.3 isoform of hif-1α in the prostate cancer cell line
PC3 but not in the less aggressive LNCaP cells. We also demonstrate
that TLR3 stimulation of PC3 cells induces HIF-1α–dependent vascular
endothelial growth factor (VEGF) secretion and resistance to poly(I:C)–
induced apoptosis, whereas these responses to poly(I:C) are obtained
in LNCaP cells, only forcing overexpression of the hif-1α- I.3 isoform.
Taken together, our results suggest that the levels of HIF-1α in prostate
cancer cells might play a crucial role in the antitumor potential of
TLR3 stimulation.
Materials and Methods
Cell Lines and Reagents
LNCaP and PC3 prostate cancer cells were purchased from ATCC
(Manassas, VA) and were grown in Dulbecco modified Eagle medium
(DMEM) supplemented with 2 mM L-glutamine, 100 IU/ml penicillin-
streptomycin, and 10% fetal calf serum (FCS; Sigma-Aldrich, St Louis,
MO). For all the experiments, prostate cancer cell lines were serum-
starved for 18 hours and then stimulated with poly(I:C) (InvivoGen,
SanDiego, CA) in FCS-free medium.Human umbilical vein endothe-
lial cells (HUVECs) were maintained in EGM-2 complete medium
(Lonza, Basel, Switzerland). Actinomycin D (Act D), cycloheximide
(CHX), and cobalt chloride (CoCl2) were from Sigma. MG-132 was
from Calbiochem-Merck (Darmstadt, Germany).
Western Blot Analysis and Nuclear Extracts Preparation
Cell lysates were prepared in cell lysis buffer (Cell Signaling,
Danvers, MA). Equal amounts of proteins (40 μg) were subjected
to SDS–polyacrylamide gel electrophoresis and were transferred onto
a nitrocellulose membrane saturated with 5% nonfat dry milk in
Tris-buffered saline with 0.1% Tween 20. Membranes were incubated
with primary antibody and subsequently with horseradish peroxidase–
conjugated secondary antibody for 1 hour at room temperature. Mem-
branes were washed with Tris-buffered saline with 0.1%Tween 20 and
developed using the chemiluminescence system (Amersham Bio-
science, Piscataway, NJ). Antibody anti–HIF-1α was from BD Bio-
sciences (San Diego, CA), cleaved caspase-3 (Asp175) was from Cell
Signaling, and anti–β-actin was from Sigma. Secondary antibodies
were horseradish peroxidase–conjugated goat antimouse or antirabbit
(Bio-Rad, Hercules, CA).
To perform Western blot analysis of nuclear extracts, cells were
washed in ice-cold PBS, scraped, collected in buffer A (10 mM Tris,
pH 7.8, 1.5 MmMgCl2, and 10 mMKCl), and kept on ice for 10 min-
utes before Dounce homogenization. Nuclei were then pelleted at 1000g
for 7 minutes at 4°C, resuspended in 150 μl of ice-cold lysis buffer, incu-
bated for 30 minutes on ice in the presence of proteases inhibitor cocktail
(Sigma), and then stored at −80°C. Protein concentrationwas determined
by the micro bicinchoninic acid method (Pierce, Rockford, IL).
Transfection Assay
One day after plating (1 × 105 cells/ml), cells were transiently
transfected with 1 μg of a plasmid encoding I.3 isoform of hif-1α [6]
or relative control plasmid (pcDNA3) or with 1μg of a plasmid contain-
ing an interfering sequence targeting hif-1α (int.hif-1α) or the relative
control (int. scramble) previously described [33]. Cells were transfected
for 5 hours with Lipofectamine LTX/plus (Invitrogen, Carlsbad, CA)
according to the manufacturer’s protocol. Stimulation with poly(I:C)
was performed 18 hours later.
To obtain stably transfected PC3 cells with nonfunctional TLR3,
cells were transfected with 1 μg of TLR3 dominant-negative plasmid
(TLR3-DN; pZERO-hTLR3; InvivoGen) or with 1 μg of plasmid con-
taining only the resistance to puromycin (pPURO), using Lipofectamine
LTX/plus as described previously. Forty-eight hours later, the cells were
trypsinized and seeded at different dilutions onto 100-mm plates in com-
pleteDMEMsupplementedwith 2μg/ml puromycin (InvivoGen). After
incubating at 37°C for 2 to 3 weeks, individual colonies were isolated
using sterile cloning rings, trypsinized, and plated onto 12-well plates.
The clones obtained were expanded and maintained in DMEM sup-
plemented with 2 μg/ml puromycin.
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Total DNA was extracted using TRIzol reagent (Invitrogen) accord-
ing to the manufacturer’s protocol, and to confirm the presence of
TLR3-DN plasmid in the clones selected, semiquantitative polymerase
chain reaction (PCR) was performed using 1 μg of total DNA, specific
primers (10 μM) (forward, 5′-GAACGTTCTTTTTCGCAACG-3′;
reverse, 5′-CTCATTGTGCTGGAGGTTCA-3′), and 1.5 U of Taq
DNA polymerase (Invitrogen). Data were normalized for the expres-
sion of β-actin.
RNA Extraction and Real-time Quantitative Reverse
Transcription–PCR Analyses
Total RNA was extracted using TRIzol reagent (Invitrogen) and
used 3 μg for the reverse transcription reaction by using a SuperScript
First-Strand Synthesis System Kit (Invitrogen). One microgram of
total complementary DNAwas used for quantitative reverse transcrip-
tion (qRT)–PCR analysis performed in triplicate for each sample.
cDNA was mixed with 0.5 μM of both forward and reverse primers
and with 20 μl of Master Mix (SYBRGreen JumpStart; Sigma). Reac-
tions were performed by a 7500 Fast Real-time PCR System (Applied
Biosystems, Carlsbad, CA). Primer sequences were as follows: generic
hif-1α, forward 5′TGGCCTTGTGAAAAAGGGT3′ and reverse 5′
TTGATGGGTGAGGAATGGGT3′; and veg f, forward 5′CCTT-
GCTGCTCTACCTCCAC3′ and reverse 5′TGGTGATGTTG-
GACTCCTCA3′. Amounts of the specific isoform of hif-1α were
estimated by the comparative C t method using ribosomal protein L32
messenger RNA (mRNA; forward 5′CATCTCCTTCTCGGCAT-
CA3′ and reverse 5′AACCCTGTTGTCAATGCCTC3′) and I.3 iso-
form mRNA (forward 5′TGGTGGTTACTCAGCACTTTTA-GA3′
and reverse 5′CTCCGACATTGGGAGCTCAT3′).
ELISA
The level of VEGFwas evaluated byELISA (R&DSystems,Minnea-
polis, MN) according to the manufacturer’s protocol and was normal-
ized to the number of adherent cells counted at the time of collection.
In Vitro Morphogenesis
A total of 5 × 104 HUVECs were seeded in 48-well microtiter
plates containing polymerized Matrigel and incubated with condi-
tioned medium (CM) obtained from either untreated or poly(I:C)–
treated cells or in the presence of specific human VEGF neutralizing
antibody (1 μg/ml; R&D Systems). After 6 hours, cells were fixed with
4% formaldehyde in PBS for 30 minutes at room temperature, washed,
and stored in PBS at 4°C. The number of cell intersections in six ran-
dom microscopic fields was counted in triplicate wells at 10× origi-
nal magnification, using the inverted phase-contrast microscope Leitz
Fluovert (Wetzlar, Germany).
Apoptosis Assay
For propidium iodide (PI) staining, cells were detached with trypsin,
washed with cold PBS plus 5% FCS, and then fixed in 70% ethanol for
24 hours. After washing with PBS, cells were incubated with 1 μg/ml
PI for 3 hours at 25°C before FACS analysis by a Coulter Epics XL flow
cytometer (Beckman Coulter, Fullerton, CA). Cells were considered
apoptotic when their DNA content was <2N (sub-G1 cell population).
Results were analyzed with Win MDI software (Scripps Research In-
stitute, La Jolla, CA) and were presented as a percentage of specific ap-
optosis determined using the following formula: [(% apoptotic cells in
experimental sample −% apoptotic cells in control sample) / (100 −%
apoptotic cells in control sample) × 100].
Statistical Analysis
Statistical differences were determined either by Student’s t test for
paired samples or by one-way analysis of variance followed by Student’s
t test with the Bonferroni correction. P ≤ .05 was considered signifi-
cant. Densitometric analysis was performed using AIDA software.
Results
HIF-1α Is Upregulated by Poly(I:C) in PC3 Cells
Because it has been reported that the TLR4 and 7/8 agonists induce
hypoxic genes inmacrophages in normoxic condition [19,20], we exam-
ined the possibility that TLR3 stimulation couldmodulateHIF-1α pro-
tein in PC3 cells. Cells were treated with the TLR3 agonist poly(I:C)
and levels of HIF-1α determined by Western blot. As shown in
Figure 1A, poly(I:C) induces a marked up-regulation of HIF-1α levels
in total cell lysates. Because activated HIF-1α rapidly moves into the
nucleus, cells were treated with increasing doses of poly(I:C) for
6 hours, and HIF-1α expression was evaluated in nuclear extracts.
As shown in Figure 1B, nuclear accumulation of HIF-1α was strongly
induced by poly(I:C) in a dose-dependent manner. Time course anal-
ysis showed that an increase of HIF-1α was first observed in the nu-
clear extracts after 6 hours of exposure to 5 μg/ml poly(I:C), and
maximal induction was obtained after 16 hours (Figure 1C ). These
results demonstrate that, in PC3 cells, stimulation with poly(I:C) in-
duces accumulation of HIF-1α and its translocation to the nucleus.
Figure 1. Poly(I:C) treatment induces time- and dose-dependent
HIF-1α nuclear accumulation in PC3 cells Western blot analysis. (A)
Cells were treated with poly(I:C) (25 μg/ml) for 16 hours, and whole-
cell extracts were analyzed for HIF-1α. (B) Cells were treatedwith the
indicated doses of poly(I:C) for 6 hours, and nuclear extracts were
analyzed for HIF-1α. (C) Nuclear extracts from cells treated with
5 μg/ml poly(I:C) for the indicated times. β-Actin was used as control
for equal amounts (30μg/lane) of protein loaded. Data shown are typ-
ical of three separate experiments with similar results.
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HIF-1α Accumulation on Poly(I:C) Treatment Is Mostly
Accounted for by the Induction of a Specific Isoform
of HIF-1α mRNA
It is well known that protein stabilization is the predominant mech-
anism by which HIF-1α protein is increased during hypoxia, whereas
the regulation of HIF-1 under normoxic conditions is less clear [7]. As
several articles reported that increased transcription of the hif-1α gene
accounts for HIF-1α protein induction under normoxic conditions
[34], we hypothesized that this mechanism could be implicated in
the induction of HIF-1α by poly(I:C) in PC3 cells and investigated
whether hif-1α mRNA was directly upregulated in a time course
qRT-PCR experiment. A statistically significant increase in the levels
of hif-1αmRNAwas induced within 4 hours of poly(I:C) stimulation,
and a further boost was observed after 6 hours (Figure 2A). To confirm
that the increase of hif-1α mRNA is important for elevated protein
levels, PC3 cells were treated with poly(I:C) for 6 hours, then tran-
scriptional inhibitor Act D or protein synthesis inhibitor CHX were
added and incubated for 15 minutes. Figure 2B (upper panel ) shows
that both Act D and CHX completely abolished poly(I:C)–dependent
HIF-1α protein induction, whereas in cells treated with CoCl2, a chem-
ical hypoxia-mimic that induces stabilization of HIF-1α protein, CHX
and Act D did not inhibit HIF-1α protein accumulation, as expected.
Indeed, this observation is consistent with previous studies showing that
CoCl2 as well as hypoxia had no effect on HIF-1α protein synthesis but
blocked its degradation. On the contrary, our results indicated that the
induction of HIF-1α protein by poly(I:C) needed de novo synthesis of
both hif-1αmRNA and protein in PC3 cells. Next, we analyzed whether
poly(I:C) enhances HIF-1α protein stability, and to this end, we treated
PC3 cells with the proteasome inhibitor MG-132 to block the degra-
dation of HIF-1α. As shown in Figure 2B (lower panel ), in the absence
of poly(I:C), MG-132 induced an increase in the level of HIF-1α.
When the MG-132–treated cells were also exposed to poly(I:C), we
observed a substantial increase of HIF-1α protein level compared with
MG-132 alone, whereas the addition of CHX reverted the increase to
the level of MG-132 alone, confirming a crucial role of de novo synthesis
of HIF-1α protein in poly(I:C)–induced HIF-1α accumulation. In con-
trast, exposure of PC3 cells to CoCl2 combined withMG-132 resulted in
a greater increment of HIF-1α compared with CoCl2 alone, an increase
which was not significantly inhibited by CHX, as expected (Figure 2B,
lower panel ). In accordance with this result, we did not observe, after
poly(I:C) treatment, reactive oxygen species accumulation, which has
been implicated in TLR-mediated HIF-1α stabilization because of the
down-regulation of prolyl hydroxylase [35] (data not shown).
Because we recently described a novel mRNA isoform I.3 of HIF-1α
that is upregulated in activated humanT lymphocytes, we investigated the
levels of different hif-1α isoforms in PC3 cells and their regulation
through TLR3. Because the primers used for the previously mentioned
qRT-PCR amplify both I.1 and I.3 hif-1α isoforms, we used isoform-
specific primers to study which isoform of hif-1α was induced by
poly(I:C). As shown in Figure 2C , I.1 isoform of hif-1α gene, canoni-
cally activated by hypoxia, is not affected by poly(I:C) stimulation,
whereas I.3 isoform mRNA is upregulated after 6 hours of treatment
Figure 2. Poly(I:C) stimulation specifically induces the I.3 isoform
of HIF-1α in PC3 cells. (A) Cells untreated or treated with 5 μg/ml
poly(I:C) for the indicated timeswere analyzed for hif-1αmRNA levels
by qRT-PCR. Each point represents the mean of triplicate samples
from three independent experiments with SD as error bars, *P ≤
.05. (B) Cells were treated with 5 μg/ml poly(I:C) for 5 hours 45 min-
utes and then with CHX (2 μg/ml) or Act D (2 μg/ml) for 15 minutes
(upper panel). Cells were treated with 5 μg/ml poly(I:C) for 20 hours
30minuteswith orwithout 5 μg/mlMG-132 for the last 3 hours in the
presence or absence of CHX (2 μg/ml) for 30 minutes (lower panel).
Treatmentwith 100 μMCoCl2 for 3 hourswas used as hypoxic stim-
ulus. HIF-1α protein was detected by Western blot on whole-cell
lysates. β-Actin was used as loading control. (C) qRT-PCR with spe-
cific primers was used to evaluate the different hif-1α isoforms in-
duced after poly(I:C) stimulation. Data shown in panel B are typical
of three separate experiments with similar results. The histogram in
panel C represents the mean of triplicate samples from three inde-
pendent experiments with SD as error bars, *P ≤ .05, **P ≤ .01.
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at the same degree observed in qRT-PCR for total hif-1α mRNA
shown in Figure 2A.
Poly(I:C)–Induced HIF-1α Accumulation Is TLR3-Dependent
Different molecules besides TLR3 are involved in dsRNA recog-
nition, because poly(I:C) is able to activate also different pathways
mediated by cytosolic sensors [36,37]. To determine whether the
observed HIF-1α accumulation was directly dependent on TLR3
stimulation, we produced a PC3 cell line (PC3-TLR3-DN) stably trans-
fected with a dominant-negative form of TLR3 (pZERO-hTLR3) and
another (PC3-PURO) with a plasmid containing solely the resistance to
puromycin. DNA analysis with specific primers showed the presence
of the pZERO-hTLR3 plasmid only in the PC3-TLR3-DN cells (Fig-
ure 3A). Hence, both transfected clones were treated with poly(I:C),
and the increase in hif-1α mRNA and nuclear protein accumulation
were evaluated by qRT-PCR and Western blot, respectively. As shown
in Figure 3, B and C , the expression of TLR3-DN completely inhibits
poly(I:C)–inducedHIF-1α transcription and nuclear protein accumu-
lation, whereas HIF-1α up-regulation was confirmed in poly(I:C)–
treated PC3-PURO control cells. These data demonstrate the key role
of TLR3 inmediating the induction ofHIF-1α triggered by poly(I:C).
Poly(I:C) Induces HIF-1α–Mediated VEGF Transcription
and Secretion
To test whether the enhanced HIF-1α protein level induced by
poly(I:C) is paralleled by an increase in its transcriptional activity,
PC3 cells were stimulated with poly(I:C) for different lengths of time,
and transcription of veg f, a known HIF-1 target gene, was analyzed by
qRT-PCR. VEGFmRNA levels were significantly enhanced in PC3 cells
after 16 and 24 hours of poly(I:C) treatment (Figure 4A). Using ELISA,
we also evaluated the amount of VEGF secreted by poly(I:C)–treated
PC3 cells, in CM collected at various time points during poly(I:C) stim-
ulation. The kinetics of VEGF accumulation is subsequent to the in-
duction of veg fmRNA, with a significant increase of VEGF protein in
PC3-CM already detectable after 24 hours of stimulation and strong
accumulation after 48 hours (Figure 4B). To validate the angiogenic
potential of VEGF secreted under poly(I:C) stimulation, the tubulo-
genic activity of CM was tested on the endothelial cell line HUVEC.
As shown in Figure 4, C and D, poly(I:C)–treated PC3 cell CM was
found to stimulate the formation of more capillary-like structures than
the CM from control PC3 cells. Moreover, anti-VEGF antibody sig-
nificantly reverted this proangiogenic function, confirming that VEGF
is the main mediator of poly(I:C)–induced in vitro angiogenesis
(Figure 4D). No direct effect of poly(I:C) on tubulogenesis was observed
(Figure 4D). To clearly demonstrate the involvement of HIF-1α in the
stimulation of VEGF secretion, PC3 cells were transiently transfected
with a vector encoding an RNA interference targeting hif-1α (int.
HIF-1α) or with a vector encoding a scramble RNA interference se-
quence (int.scramble). At first, we verified that poly(I:C)–induced
HIF-1α protein was significantly reduced in cells with int.HIF-1α
(Figure 4E ). Transfected cells were treated with poly(I:C) for 24 hours,
and veg f expression was analyzed by qRT-PCR. The RNA interfer-
ing against hif-1α, but not scramble sequence, significantly inhib-
ited poly(I:C)–induced veg f transcription (Figure 4F ), demonstrating
that poly(I:C) can induce VEGF production by increasing HIF-1α
protein expression and the formation of a transcriptionally active
HIF-1 complex.
Poly(I:C) Induces VEGF Secretion in LNCaP Cells
Overexpressing I.3 hif-1α Isoform
It has been published that LNCaP cells have the lowest HIF-1α
levels among human and rat PCa cell lines, suggesting that HIF-1α
expression may increase in cancer progression [38]. Therefore, we
studied whether TLR3 stimulation can induce HIF-1α nuclear accu-
mulation also in LNCaP cells and found that poly(I:C) stimulation
failed to induce nuclear accumulation of HIF-1α (Figure 5A). Total
lysates of LNCaP cells treated with CoCl2 were used as positive con-
trol of HIF-1α accumulation. The poly(I:C)–independent weak ac-
cumulation of HIF-1α at 24 hours is an effect of serum starvation, as
previously described [39]. To study the effects of I.3 hif-1α overex-
pression in LNCaP cells treated or not with poly(I:C), we transfected
Figure 3. Poly(I:C)–induced HIF-1α accumulation is TLR3-dependent.
(A) PC3 cells stably transfected with a plasmid containing the
dominant-negative form of TLR3 (PC3-TLR3-DN) or with a plasmid
containing only the resistance to puromycin (PC3-PURO) were sub-
jected to total DNA extraction, and the presence of the TLR3-DN
plasmid was assessed using PCR with specific primers. Nontrans-
fected PC3 cells and the plasmid used for the transfection (pZERO-
hTLR3) were used as negative and positive controls, respectively.
β-Actin was used as a control for equal amounts of DNA loaded.
(B and C) Both stably transfected cell lines were treated for 6 hours
with 5 μg/ml poly(I:C), and the increase of hif-1αmRNA and nuclear
protein accumulation were evaluated by qRT-PCR (B) and Western
blot analysis (C). β-Actin was used to normalize both qRT-PCR and
Western blot. Data shown in panels A and C are typical of three sep-
arate experimentswith similar results. The histogram in panel B rep-
resent the mean of triplicate samples from three independent
experiments with SD as error bars, *P ≤ .05.
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Figure 4. Poly(I:C) increases the production of active VEGF through HIF-1α. (A and B) vegf mRNA and protein levels of PC3 cells were
evaluated after 5 μg/ml poly(I:C) stimulation for the indicated time points using qRT-PCR (A) and ELISA (B), respectively. (C and D) Forma-
tion of capillary-like structures. Representative phase-contrast microphotographs of capillary-like structures (C) and quantitative evaluation
of their morphogenesis in HUVEC cultures (D). HUVECs were exposed to supernatants of PC3 cells untreated (ctr) or treated with poly(I:C)
for 48 hours in the presence or absence of VEGF neutralizing antibodies (anti-VEGF Ab). HUVEC exposed to serum-free medium (DMEM)
with or without poly(I:C) for 48 hours were used as negative controls. (E) Cells were transiently transfected with a vector encoding an RNA
interfering hif-1α (int. hif-1α) or with a vector encoding a scramble RNA sequence (int. scramble), then treated with 5 μg/ml poly(I:C) for
6 hours and analyzed for total HIF-1α protein level using Western blot. β-Actin was used as a control for equal amounts of protein loaded.
(F) Transfected cells were treated with poly(I:C) for 24 hours, and vegf mRNA expression was evaluated by qRT-PCR. The histograms in
A, B, D, and F represent themean of triplicate samples from three independent experimentswith SD as error bars, *P≤ .05, **P≤ .01. Data
shown in panel E are typical of three separate experiments with similar results.
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Figure 5. Overexpression of I.3 hif-1α in LNCaP cells determines poly(I:C)-induced VEGF production. (A) LNCaP cells were treated for
the indicated times with 25 μg/ml poly(I:C), and Western blot analysis of HIF-1α was performed on nuclear extracts. Cells treated with
100 μMCoCl2 for 3 hourswere used as positive control for HIF-1α accumulation. β-Actinwas used as a loading control. (B, C, andD) LNCaP
cells were transiently transfected with a plasmid containing the I.3 isoform of HIF-1α (hif-1α I.3) or with a control plasmid (pcDNA3). Cells
were then treated with 5 μg/ml poly(I:C) for 6 hours, and HIF-1α protein levels were analyzed usingWestern blot (B). Analysis of the I.1 and
I.3 isoform of hif-1α mRNA was performed by using qRT-PCR (C). ELISA was used to analyze VEGF concentration in the CM of untrans-
fected or transfected cells with the indicated plasmids and then treated or left untreated with poly(I:C) (D), the histogram represents the
mean ± SEM of three independent experiments. **P ≤ .01. Data shown in panels A and B are typical experiments repeated three times
with similar results. Histograms in panels C andD represent themean of triplicate samples from three independent experimentswith SDas
error bars, *P ≤ .05, **P ≤ .01.
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this cell line with a plasmid containing I.3 isoform of hif-1a (hif-1a I.3)
and treated the cells with poly(I:C). Overexpression of hif-1a I.3 iso-
form in LNCaP cells induced a slight increase of HIF-1α protein,
strongly raised on poly(I:C) treatment (Figure 5B). The mechanism
of poly(I:C)–induced HIF-1α accumulation in transfected LNCaP
cells was further investigated by qRT-PCR and revealed that the trans-
fection with hif-1a I.3 induces a 2000-fold accumulation of this mRNA
compared with untransfected LNCaP cells and that poly(I:C) stimula-
tion induces a further five-fold accumulation above the basal levels of the
transfected cells (Figure 5C , right panel ). The left panel of Figure 5C
shows that I.3 isoform transfection causes I.1 hif-1amRNA to increase
by approximately three-fold over the basal levels and that poly(I:C) fails
to induce additional accumulation. These data confirm the induction of
the specific I.3 isoform of hif-1α mRNA by poly(I:C), suggesting an
important role of the basal levels of this isoform in this process. To un-
derstand whether poly(I:C)–induced HIF-1α protein was functional in
hif-1α I.3–transfected LNCaP cells, we checked for VEGF accumula-
tion in LNCaP CM by ELISA. Figure 5D shows that poly(I:C) fails to
induce VEGF accumulation in LNCaP cells transfected with pcDNA3
control plasmid, in accordance with the lack of HIF-1α accumulation
shown in Figure 5A. In the CM of the cells transfected with the I.3 plas-
mid, the accumulation of VEGF is only weak with respect to the me-
dium of the cells transfected with the control plasmid, but a very strong
accumulation of VEGF is detectable in the medium of the cells trans-
fected with hif-1α I.3 and then treated with poly(I:C) (Figure 5D).
HIF-1α Levels Regulate Poly(I:C)–Induced Apoptosis in PC3
and LNCaP Cells
So far, we have demonstrated that, unlike PC3 cells, LNCaP cells fail
to undergo HIF-1α increase on TLR3 stimulation. Given that previous
articles reported an antiapoptotic effect for HIF-1α [40] and given the
low sensitivity of PC3 cells to poly(I:C)–induced apoptosis [27], we hy-
pothesized a role ofHIF-1α in their resistance to this apoptotic stimulus.
To test this hypothesis, PC3 cells were transfected with int.HIF-1α
or with int.scramble, treated with poly(I:C), and apoptosis induction
was analyzed. PI staining revealed that PC3 cells transfected with int.
HIF-1α were more susceptible to poly(I:C)–induced apoptosis than
the cells transfected with int.scramble (Figure 6A). Moreover, Western
blot analysis of the activated form of caspase-3 showed that induction
of this apoptotic effector is stronger in cells transfected with int.hif-1α
than that transfected with int.scramble, confirming the importance of
HIF-1α in regulation of apoptotic susceptibility.
To confirm the antiapoptotic function of the poly(I:C)–induced
HIF-1α protein observed in PC3 cells, we transfected LNCaP cells
Figure 6. Up-regulation of HIF-1α inhibits poly(I:C)–induced apoptosis in LNCaP andPC3 cells. PC3 cells transfectedwith scramble or hif-1α
interfering plasmids, treated or not with 5 μg/ml poly(I:C) for 24 hours, were analyzed for the apoptotic rate using PI staining (A) and
caspase-3 activation (B). LNCaP cells overexpressing I.3 isoform of hif-1α were treated with 5 μg/ml poly(I:C) for 24 hours, and PI staining
(C) and caspase-3 activation (D) were performed to evaluate the apoptotic rate. Histograms in panels A and C represent the mean of tripli-
cate samples from three independent experiments with SD as error bars, **P≤ .01. Data shown in panels B and D are typical experiments
repeated three times with similar results.
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with the plasmid containing I.3 hif-1α. Transfected LNCaP cells were
treated with poly(I:C), and their apoptotic rate was evaluated by flow
cytometry. Figure 6C shows that the sub-G1 population represents
12% of I.3 hif-1α–transfected cells after poly(I:C) treatment, whereas
this population significantly increases (up to approximately 25%) in
cells transfected with the control plasmid and treated with poly(I:C).
We also analyzed caspase-3 activation in transfected LNCaP cells treated
or not with poly(I:C) and observed that activation of caspase-3was lower
in the cells transfected with I.3 hif-1α than in the cells transfected with
the control plasmid (Figure 6D).
Discussion
Nonhypoxic stimuli such as lipopolysaccharide (LPS), interleukin-1β
(IL-1β), insulin growth factor (IGF), and tumor necrosis factor α
(TNFα), usually associated with inflammatory conditions, have been
described to induce HIF-1α protein accumulation and transcription
of HIF-1 target genes in several cellular models [7]. Stimulation of
TLRs by microbial components may represent the signal promoting
a proinflammatory environment that enhances tumor growth and che-
moresistance. Here we report that stimulation of TLR3 with poly(I:C)
can increase HIF-1α mRNA and HIF-1α protein nuclear translo-
cation in the highly aggressive prostate cancer cell line PC3. A recent
article reported that transfected poly(I:C) induces HIF-1α in a glio-
blastoma cell line, suggesting a role of this transcription factor in re-
sponse to viral infection [41]. Here we extend to prostate cancer cells
the involvement of HIF-1α in poly(I:C) response and, for the first
time, demonstrate a key role of TLR3 in poly(I:C)–induced HIF-1α
activation, using a TLR3 dominant-negative stably transfected PC3
cell line. In fact, whereas transfected poly(I:C) mimics intracellular
dsRNA generated during viral replication, extracellular administration
of poly(I:C) involves TLR3 activation and mimics viral infection
through the pinocytosis of dsRNA released by lysed, infected cells.
TLR agonists are under clinical trial for the treatment of various car-
cinoma and even a GMP-grade synthetic analog of poly(I:C) has been
proposed as an adjuvant for cancer immunotherapy [42], but this
strategy is currently discussed because several articles report opposite
protumor or antitumor response after TLR stimulation [43,44]. We
recently described that poly(I:C) induces a strong TLR3-mediated
apoptotic response in LNCaP cells, whereas PC3 cells seem weakly
sensitive to this stimulus [27]. The lower sensitivity of PC3 cells to
poly(I:C)–induced apoptosis compared with LNCaP cells led us to hy-
pothesize that, in the more aggressive PC3 cell line, poly(I:C) stimula-
tion may activate genes inducing an antiapoptotic response. Besides
the described antiapoptotic action of androgens [45], the resistance to
apoptosis is linked to HIF-1α function in prostate cancer [39,46].
Using an RNA interference approach, we observed a significant in-
crease of apoptosis in HIF-1α knockdown PC3 cells, demonstrating a
direct role of HIF-1α in the protection of PC3 cells against poly(I:C)–
induced apoptosis.
Beside HIF-1α–mediated antiapoptotic effect, we observed also a
consistent increase in poly(I:C)–induced VEGF production. VEGF is
one of the principal HIF-1 target genes considered the main factor re-
sponsible for the induction of neovascularization in hypoxic tumor
sites, favoring cancer progression [47]. The ability of poly(I:C) to in-
duce TLR3-dependent VEGF secretion has been recently reported in a
mesothelioma cell line [48], but the mechanism of induction was not
described. In the present article, using a plasmid containing an inter-
ference sequence for HIF-1α, we demonstrate that poly(I:C)–induced
HIF-1α activation is responsible for VEGF production in PC3 cells,
revealing a new protumor face of TLR3 signaling in prostate cancer.
HIF-1α stabilization is the key event in the induction of HIF-1
complex in hypoxic conditions, but its activation mechanism in nor-
moxic condition is still not clear, probably depending on the nature of
the stimulus and on the cell types. There is accumulating evidence
that the main mechanism implicated in the nonhypoxic induction
of HIF-1α is an increase in HIF-1α protein translation and that the
rate of degradation ofHIF-1α remains high [7]. As for themechanisms
underlying TLR3-mediated HIF-1α up-regulation, here we demon-
strated by pharmacological inhibitors that the HIF-1α increase in
PC3 cells requires new mRNA transcription and de novo protein syn-
thesis, showing for the first time that poly(I:C) enhances HIF-1α ex-
pression through a translation-dependent mechanism rather than
inhibition of protein degradation.
Regarding the different mRNA isoforms of HIF-1α, it has been ini-
tially shown that, in mice, HIF-1α is encoded by two alternative iso-
forms, which are expressed from different promoters and uses two
distinct exons: I.1 or I.2 [18,49]. The I.1 isoform, which is analogous
to the I.3 human isoform described in the present manuscript, was ex-
pressed in tissue-specific manner and was strongly induced by activa-
tion, whereas the I.2 isoform (analog of the human I.1 isoform)
demonstrated a ubiquitous pattern of expression and was present in
all analyzed tissues. Studies of the murine and human HIF-1α pro-
moters [49,50] revealed that the ubiquitous isoform is expressed con-
tinuously from the housekeeping-type CpG island-rich promoter.
Nevertheless, murine I.1 isoform and corresponding human I.3 iso-
form were shown to be dramatically upregulated by activating stimuli
in T lymphocytes [6,18], possibly because of the presence of a number
of activation response binding sites for transcriptional factors in the
promoter [49]. Thus, it was expected that the HIF-1α isoform upreg-
ulated after TLR3 activation was the I.3 but not the ubiquitous I.1 in
human cells. Here we investigated for the first time the levels of differ-
ent hif-α isoforms in tumor cells and report that activation of HIF-1
complex after poly(I:C) stimulation in PC3 cells is mainly dependent
on the transcription of the HIF-1α I.3 isoform.
A previous article reported amplification of theHIF-1α gene in PC3
cells resulting in a higher basal level of the HIF-1α protein present in
the nucleus of these cells with respect to other prostate cancer cell lines
such as LNCaP [38]. Moreover, the apoptotic signaling mechanism
triggered by poly(I:C) in LNCaP cells is mediated by PKC-α [27]
without increasing HIF-1α, whereas PKC-α seems to play a role in
HIF-1α accumulation in PC3 cells (data not shown), indicating com-
plex transduction pathways evoked by poly(I:C) in prostate cancer cell
lines, which deserves further investigation. In view of the different
features of these two cell lines, a common mechanism of HIF-1α ac-
tivation after poly(I:C) stimulation is highly unlikely. Accordingly,
our data show that poly(I:C) induced up-regulation of endogenous
HIF-1α in PC3 cells but not in LNCaP cells. Surprisingly, transfection
of the I.3 HIF-1α isoform, although enhancing approximately 2000-
fold HIF-1α basal mRNA, only slightly increased HIF-1α protein,
failing to induce VEGF secretion. Interestingly, in LNCaP cells over-
expressing exogenous HIF-1α I.3, stimulation with poly(I:C) strongly
increases HIF-1α protein, suggesting that TLR3 activation is capable
of counteracting the mechanisms that can basally control HIF-1α pro-
tein accumulation. The possibility that the effects of this forced over-
expression may partially depend on an artificial responsiveness of
the exogenous promoter cannot be ruled out. Noteworthy, poly(I:C)
stimulation of LNCaP cells overexpressing HIF-1α leads to a strong
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induction of HIF-1α and VEGF proteins paralleled by the capability
to resist to poly(I:C)–induced apoptosis. These results also demon-
strate that, in LNCaP, a high basal expression of I.3 HIF-1α is essential
for poly(I:C)–induced HIF-1α accumulation. In view of our data, the
deregulation of HIF-1α basal levels seems to be crucial in controlling
the mechanisms involved in cancer progression.
HIF-1 has become an important therapeutic target in solid tumors,
and efficient drugs capable of decreasing HIF-1 are currently under
development [51,52].Moreover, activation of hypoxic genes in prostate,
breast, and ovarian cancers as predictor of adverse clinical outcome has
been reported, suggesting that HIF-1 complex represents a key tran-
scription factor in endocrine tumors [9]. In particular, HIF-1α/β and
HIF-2α, together with abnormal estrogen receptor β and endothelial
nitric oxide synthase, have been recently described to drive prostate can-
cer toward a more aggressive phenotype [53].
In conclusion, our results are the first evidence showing a correla-
tion between HIF-1α I.3 isoform expression and ability of TLR3 to
regulate apoptosis and induce VEGF production in human tumor
cell lines. Future studies with gene-targeted knockdown of the
HIF-1α I.3 isoform may provide conclusive evidence for its role in
TLR3-mediated effects in prostate cancer, contributing to the refine-
ment of diagnostic tools and possibly the development of targeted
therapeutic strategies.
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